Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The University of Melbourne · Epworth Hospital · +33 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
577
total citations
- FWCI
- 65.15
- Percentile
- 100%
- References
- 29
Citations per year
Authors
89- HMH. Miles PrinceCorresponding
The University of Melbourne, Epworth Hospital, Peter MacCallum Cancer Centre
- YHYoun H. Kim
Cancer Prevention Institute of California, Stanford Medicine, Stanford Cancer Institute, Stanford University
- SMSarah McCue Horwitz
Memorial Sloan Kettering Cancer Center
- RDReinhard Dummer
University Hospital of Zurich
- JSJulia Scarisbrick
NIHR Surgical Reconstruction and Microbiology Research Centre
Topics & keywords
Topics
Keywords
- Brentuximab vedotin
- Medicine
- Mycosis fungoides
- Internal medicine
- Population
- Anaplastic large-cell lymphoma
- Clinical endpoint
- CD30
No related works found for this paper.